RELFINBI
Dead / Abandoned — Abandoned — no statement of use filed (as of 17 Apr 2023)
What this means for you
This application is over — abandoned 17 Apr 2023. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 97021169
- Mark type
- Stylized text
- Filed
- 10 Sept 2021
- Published for opposition
- 19 Jul 2022
- Abandoned
- 17 Apr 2023
- Attorney of record
- Brendan J. Hughes
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceuticals for the treatment of central nervous system disorders; pharmaceuticals for the treatment of neurological and psychiatric disorders; pharmaceuticals for the treatment of agitation; pharmaceuticals for the treatment of agitation associated with neuropsychiatric conditions, neurodegenerative diseases, schizophrenia, bipolar disorder, dementia, delirium, alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal, depression or any other central nervous system disorder; pharmaceuticals for the treatment of symptoms associated with alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal, depression or other central nervous system disorders
Owner
- Bioxcel Therapeutics, Inc., New Haven, CT, US
- Bioxcel Therapeutics, Inc., New Haven, CT, US
Prosecution history
- 17 Apr 2023 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 17 Apr 2023 — ABANDONMENT - NO USE STATEMENT FILED
- 13 Sept 2022 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 19 Jul 2022 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 19 Jul 2022 — PUBLISHED FOR OPPOSITION
- 29 Jun 2022 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 15 Jun 2022 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 15 Jun 2022 — ASSIGNED TO EXAMINER
- 19 Oct 2021 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 14 Sept 2021 — NEW APPLICATION ENTERED